Crestor Can Reduce Risk For Cardiovascular Events In Patients With High Levels Of Protein, Study Finds

Crestor Can Reduce Risk For Cardiovascular Events In Patients With High Levels Of Protein, Study Finds
Medical News Today
11th November 2008


The cholesterol medication Crestor, manufactured by AstraZeneca, can reduce by about half the risk for heart attack, stroke and death among patients who do not have high cholesterol levels but tested positive for high levels of a protein linked with increased risk for heart attack, according to a study presented Sunday at the annual meeting of the American Heart Association in New Orleans and published online in the New England Journal of Medicine, the Wall Street Journal reports (Winslow, Wall Street Journal, 11/10).

Latest news:
1st December 2008 - Researchers Learn That Some 'Good Cholesterol' Isn't Good Enough
1st December 2008 - New NPS Patient Resource On Infective Endocarditis, Australia
28th November 2008 - Opportunity to invest in a novel Acoustic Pressure Sensor for medical applications
27th November 2008 - Medis And TomTec Launch Joint Cardiac Imaging And Analysis Product
27th November 2008 - International Medical Team Announces Patient Results In Adult Stem Cell Clinical Study For Pulmonary Hypertension
26th November 2008 - Why Does It Take So Long For A Correct Diagnosis Of Pulmonary Hypertension?
26th November 2008 - Dramatic JUPITER Findings Fail To Sway Prescribing Behavior, Poll Shows
15th November 2008 - Statement By Merck & Co., Inc., In Response To The FDA's Update Regarding A Safety Review On Bisphosphonates Including FOSAMAX®
14th November 2008 - Arsenic May Increase Risks For Cardiovascular Disease At Current Epa-Regulated Drinking Water Standards
14th November 2008 - High-Normal Phosphate Levels Linked To Early Atherosclerosis
more news